Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Pharma, Inc. filings document a commercial-stage biopharmaceutical company focused on medicines for genetic conditions, including financial results, product revenue disclosures, program updates, and formal reports on ATTR-CM, LGMD2I/R9, and achondroplasia development programs.
Its SEC record includes Form 8-K disclosures for results of operations, Regulation FD presentations, clinical and regulatory press releases, material agreements, an at-the-market equity distribution agreement, convertible senior notes, and a board-authorized stock repurchase program. Proxy materials address director elections, executive compensation votes, auditor ratification, incentive plan share reserves, governance structure, and stockholder voting matters.
BBIO proposes the sale of 140,000 shares of Common stock as indicated on the notice.
The filing lists multiple prior 10b5-1 sales by related parties, including recent transactions by Kumar Haldea Revocable Trust and Neil Kumar on 03/12/2026 and 02/19/2026. Examples shown include 20,000 shares sold on 03/12/2026 and 28,053 shares sold on 02/19/2026.
BridgeBio Pharma director Hannah Valantine exercised stock options to acquire 8,671 shares of common stock at $27.36 per share on March 10, 2026. She then sold the same 8,671 shares at $72.00 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she holds 7,465 shares directly and 398 shares indirectly through her spouse.
Hannah A Valantine reported a Rule 144 notice to sell Common Stock. The filing shows a planned sale tied to a 03/10/2026 stock option exercise and reports a prior sale of 25,484 shares on 02/27/2026 for $1,717,779.60.
The transaction is listed through Morgan Stanley Smith Barney LLC, with the security identified as Common and the market noted as NASDAQ. The filing is a notice of proposed resale under Rule 144 rather than a Form 3/4 insider trade report.
BridgeBio Pharma, Inc. director Andrea Ellis exercised stock options and sold shares in a pre‑planned trade. On March 4, 2026, Ellis exercised options for 64,921 shares of common stock at $8.45 per share, converting a previously held stock option that had vested in three annual installments beginning on June 22, 2023 and ending on June 22, 2025. The same day, Ellis sold 64,921 shares of common stock at a weighted average price of $64.8681 per share, within a range of $64.255 to $65.21, under a Rule 10b5‑1 sales plan adopted on December 3, 2025, and held 18,589 shares directly afterward.
BridgeBio Pharma director Hannah Valantine exercised stock options for 25,484 shares on February 27, 2026, converting a “Stock Option (Right to Buy)” into common stock at an exercise price of $0.00 per share, with the resulting common shares reported at $48.45 per share.
On the same date, she sold 14,584 common shares at a weighted average price of $67.0793 and 10,900 shares at $67.8437 in open-market transactions executed under a Rule 10b5‑1 sales plan adopted on November 14, 2025. After these trades, she held 7,465 common shares directly and 398 shares indirectly through her spouse.
BridgeBio Pharma’s Chief Accounting Officer, Maricel Apuli, reported an open-market sale of 2,000 shares of common stock on February 26, 2026 at $66 per share. The transaction was executed under a pre-arranged Rule 10b5-1 sales plan adopted on September 8, 2025. Following this sale, Apuli directly holds 121,945 BridgeBio shares.
BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on genetically driven diseases, built around a hub-and-spoke portfolio model. Its lead product, Attruby (acoramidis) for transthyretin amyloid cardiomyopathy, generated $362.4 million in 2025 U.S. net product revenue, supported by 7,804 unique patient prescriptions and 1,856 prescribing clinicians.
Ex‑U.S., acoramidis is marketed as Beyonttra through Bayer in Europe and Alexion in Japan, contributing license, services, and royalty revenue after 2025 approvals. The company reports multiple late‑stage wins: positive Phase 3 data for infigratinib in achondroplasia, encaleret in autosomal dominant hypocalcemia type 1, and BBP‑418 in LGMD2I/R9, with planned NDA and MAA submissions starting in 2026.
BridgeBio is also advancing encaleret for chronic hypoparathyroidism, infigratinib for hypochondroplasia, and BBP‑812 for Canavan disease, plus an ATTR-CM antibody depleter program. Key risks highlighted include reliance on Attruby/Beyonttra, pricing and reimbursement pressure, clinical and regulatory uncertainty, manufacturing dependence on third parties, and substantial ongoing capital needs.
BridgeBio Pharma reported strong 2025 revenue growth but remains deeply loss-making as it scales commercial and late‑stage programs. Total revenues, net reached $502.1 million for 2025, up from $221.9 million in 2024, driven largely by $362.4 million in Attruby net product revenue and higher royalties from BEYONTTRA.
Operating costs and expenses climbed to $1.03 billion, mainly from a $242.3 million increase in selling, general and administrative spending to support launches, partially offset by lower R&D. Net loss attributable to common stockholders widened to $724.9 million with loss per share of $3.78.
Cash, cash equivalents and marketable securities were $587.5 million at year-end. The company issued $575.0 million of 2031 notes, executed a $300.0 million royalty deal, repaid a $459.0 million term loan and repurchased $48.3 million of stock. BridgeBio highlighted three positive Phase 3 readouts (BBP-418, encaleret, infigratinib) and is planning multiple NDA submissions beginning in the first half of 2026.